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What is already known 
 
-Medication reconciliation decrease number of errors at entrance 
-Pharmacists are efficient to perform medication reconciliation 
-medication reconciliation takes time 
 
What this study adds  
 
-Sharing drugs information between hospital and community pharmacists decrease patients 
exposition to drug-related problems  
 
-Medication reconciliation at discharge is effectiveness and should be implemented in 
hospitals 
 






Aim: To assess whether a pharmacist intervention associating medication reconciliation at 
discharge with a link to the community pharmacist reduces drug-related problems (DRP) in 
adult patients during the 7 days after hospital discharge in 22 university or general hospitals in 
France. 
Methods: We conducted a cluster randomised cross-over superiority trial with hospital units 
as the cluster unit. The primary outcome was a composite of any kind of DRP 
(prescription/dispensation, patient error or gap due to no medication available) during the 7 
days after discharge, assessed by phone with the patient and community pharmacist. Among 
secondary outcomes, we studied self-reported unplanned hospitalisations at day 35 after 
discharge and severe iatrogenic problems. 
Results: 1,092 patients were enrolled in 48 units (538 in the experimental periods and 554 in 
the control periods). Three patients refused to have their data analysed and were excluded 
from the analyses. As compared with usual care, the pharmacist intervention led to a lower 
proportion of patients with at least one DRP (44.0% vs 50.6%; odds ratio [OR] 0.77, 95% 
confidence interval [CI] 0.61 to 0.98) and severe iatrogenic problems (5.2% vs 8.7%; OR 
0.57, 95% CI 0.35 to 0.93) but no significant difference in unplanned hospitalisations at day 
35 (5.8% vs 4.5%; OR 1.46, 95% CI 0.91 to 2.35). 
Conclusion: Medication reconciliation associated with communication between the hospital 
and community pharmacist may decrease patient exposure to DRP and severe iatrogenic 
problems but not unplanned hospitalisation. However, this intervention could be 
recommended in health policies to improve drug management. 









Drug-related problems are defined as an “event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes” [1]. Studies suggest that at 
least 50% of patients experience drug-related problems after discharge, and 19% to 23% 
experience an adverse event that could be partially avoided [2,3]. The number of medication 
errors that occur in elderly patients due the discrepancies at discharge is about 1.5 per patient 
but can be very important from 0 to 11 [2]. Errors can be due to errors at admission (wrong 
regimen, drug omitted…) not being corrected properly, but also because of therapy changes 
not being documented. 
In the United States, 19.6% of Medicare patients are readmitted to the hospital within 90 days 
of discharge. Most readmissions are avoidable, and only 10% are planned [4]. 
In France, drug dispensation combining medication review, drug delivery and information to 
patients is mandatory for in-patients. Medication reconciliation at admission and/or discharge 
occurs in few hospitals. At hospital discharge, the continuum of care includes any prescribing 
of medications if needed and ensuring that the patient has a full understanding of 
prescriptions. This is the purpose of medication reconciliation, defined as the formal process 
of checking the complete, accurate list of a patient’s previous medications and comparing it 
with the prescriptions after a transition of care (on admission, after transfer to another medical 
unit, and at discharge), rectifying discrepancies and informing  both the patient and his/her 
caregiver  [5]. Medication reconciliation before discharge was found effective in decreasing 
drug-related problems by 50%, with higher efficiency when performed by a pharmacist versus 
a physician or nurse [6-10]. The US Joint Commission on Accreditation has recommended 
this process to prevent errors since 2005 [11]. In the UK NICE recommends that medicines 
reconciliation is carried out for people taking one or more medicines [12]. The 
recommendation 1.3.3 specifies that medication reconciliation should be carried out in 
primary care for all patients who have been discharged from hospital and before a new 
prescription or a new supply of medicines is issued. 
However, deficits in communication and information transfer between hospital discharge and 
community care have been demonstrated in several studies [3]. Several experiments have 
been conducted in North America and Europe to increase the quality of patient's information 




[13, 114]. However, few studies have focused on the role of the community pharmacist at 
discharge [15-17]. In France, many patients always go to the same community pharmacy, 
which offers a great opportunity for community pharmacists to play an important role. 
Our trial investigated the impact of an intervention with two components: 1) a hospital 
pharmacist performing medication reconciliation at discharge and 2) the hospital pharmacist 
in charge of the medication reconciliation informing the community pharmacist of any drug 
modification. We assessed whether such an intervention affects the rate of drug-related 
problems in patients during the 7 days after discharge.  
 
METHODS 
This study was registered at ClinicalTrials.gov (NCT02006797) on December 5, 2013, and 
the protocol was previously published [18]. A complete description of the different steps is 
reported in Figure 1 using the Timeline cluster tool of Caille et al. [19] 
Design 
We designed a superiority cluster randomised cross-over controlled trial. Clusters were 
hospital units, each involved during two consecutive 14-day periods: an intervention and a 
control period. Randomising clusters rather than patients allowed us to provide differential 
information to patients according to the group they were recruited in. This process is 
described in the Figure 1. Randomizing patients would probably also have resulted in several 
patients refusing to be recruited because of the very nature of the intervention assessed (cf 
infra). The cross-over feature of the design was motivated by the gain in power and the 
expected benefit of a baseline characteristic balance between groups. It was considered 
possible because of minimal risk of a carry-over effect. 
 
Settings and participants 
Hospitals all over France — half of them being university hospitals — were involved. The 
recruitment of hospitals was as follows: all university hospitals were asked to participate and 
all those that accepted were retained. For non-university hospitals, the recruitment depended 
of their location (each area had to be represented) and their existing experience in clinical 




and one medical). Units that already had a medication reconciliation procedure led by a 
pharmacist at discharge were not eligible. All adult patients were eligible, except those who f 
stayed in the hospital longer than 21 days, who did not return home, who were in a moribund 
status, or who were not able to understand the topic of the study or complete a questionnaire. 
All French community pharmacists were informed of the study, but we included only those 
who typically dispensed drugs to at least one of the patients enrolled in the study. 
Intervention 
In each group, the intervention was applied at the patient level. For some hospitals, hospital 
pharmacists were recruited specifically for the study. To standardize this intervention over the 
different hospitals [20], hospital pharmacists received a 1-day training about the reconciliation 
procedure by an experienced clinical pharmacist accredited by the French Society of Clinical 
Pharmacy (SFPC). This trainer was a clinical pharmacist professor who had established 
medication reconciliation in his hospital 5 years ago and had participated in the High 5s 
MEDREC project [21]. 
Experimental intervention (Figure 2) 
For patients included during experimental periods, hospital pharmacists performed the 
medication reconciliation at discharge. Of course, medication reconciliation at admission was 
performed as was drug dispensation for in-patients. Then hospital pharmacists completed a 
short form documenting the reason for hospitalisation, home medication modifications, new 
medication and laboratory results necessary for community pharmacists to understand and/or 
accept the prescription (estimated glomerular filtration rate, Na and K levels, coagulation 
results, etc.). They also checked the discharge prescriptions (drug added and/or omitted, 
different dosage, route or duration of treatment) and, if needed, made an intervention on 
physician’s prescription according to SFPC standard (figure3) to change prescription [22]. 
Then, they explained to the patient the drug initiated and the modifications to the home 
medication. They phoned the patient’s community pharmacist to explain the patient’s 
inclusion in the study, the discharge time, and the modifications in treatment. They also sent 
the prescription sheet to the community pharmacist before patient discharge. The patient or 





For the control group, patients received usual care already implemented both at the hospital 
(classical drug dispensation by staff pharmacists) and by their community pharmacist (drug 
dispensation according the prescription sheet written by the hospital physician in addition to 
the general practitioner’s sheet [if it existed]). For one hospital, medication reconciliation at 
admission was already implemented before the study. 
Outcomes 
The primary outcome was a composite outcome of drug-related problems occurring for any of 
the drugs the patient had to take, whatever the drug. Three types of problems were considered: 
1) the drug was not the correct one (name, form, route, or dose) because of a prescription 
and/or dispensing error; 2) the patient did not take what was prescribed and/or took drugs that 
should have been stopped (patient error); and 3) the patient could not obtain the drug when 
visiting the pharmacy, which caused a gap in the continuity and duration of therapy (treatment 
gap). The primary outcome was assessed at day 7 (±2 days) after discharge. Two pharmacists 
specifically recruited for the study contacted all included patients (or their caregiver) by 
phone to identify any problem related to drugs observed during the 7 days after discharge. 
Community pharmacists were also called on day 7 (2), to check that drugs had been 
delivered (third type of problem).  
Each identified drug-related problem was secondarily assessed by an expert committee 
consisting of one nephrologist, one cardiologist, one gastroenterologist, and one clinical 
pharmacist. They assessed the potential medical impact of drug-related problems in terms of 
severity according to the National Coordinating Council for Medication Error Reporting and 
Prevention (NCC MERP) classification [23], score 0 indicating “no potential harm”; 1, “low 
potentiality of harm”; 2, “significant potentiality of harm”; and 3, “potentially life-
threatening”. Physicians independently scored each identified problem. They also provided a 
general score to the patient, taking into account all the different problems identified for a 
patient. Discrepancies were discussed to reach a consensus. 
Each component of the primary outcome (i.e., the three types of problems) was also 
individually considered as a secondary outcome. We also assessed the number of unplanned 
hospitalisations during the 35 days after discharge (declared by patients or their caregiver). 
Patient and community-pharmacist satisfaction were evaluated by using a four-point Likert 
scale. Finally, we assessed the duration of the intervention (medication reconciliation and 




the proportion of drugs initially prescribed by the physician at discharge and modified by the 
hospital pharmacist. 
Blinding 
The very nature of the assessed intervention did not allow for blinding, except for the 
members of the expert committee who assessed the potential medical impact of the identified 
problems. Pharmacists who contacted patients by phone at days 7 and 35 were not blinded. 
Indeed, we considered that blinding would have been compromised very easily during the 
phone contacts. However, although patients recruited during experimental periods were fully 
informed of the study, its aim, and the intervention assessed, patients recruited during control 
periods were just asked whether they would agree to be contacted by phone at days 7 and 35. 
Randomisation 
For each unit, we randomly assigned the order of the two periods. Randomisation was 
stratified by hospital, for logistical convenience. Because we expected to include two units per 
hospital, one unit was first included in the experimental period and the other in the control 
period. The randomisation sequence was generated by a statistician from INSERM CIC 1415 
by using a computerized process. Units were randomised all at once. However, for logistical 
reasons, hospitals were activated sequentially, in an order that was randomly defined. Doing 
so allowed for the easiest implementation of the study in the different hospitals and easier 
management of outcome assessment, which was centralised and done by phone. 
Ethical issues 
The study was approved by the local ethics committee who agreed on a waiver of patient 
written consent. Thus, patients were informed in a different way according to the group they 
were recruited in, and were included after oral consent. 
Sample size 
We expected a reduction of drug-related problems from 60% [24] to 45%. Considering 90% 
power and a 5% two-sided alpha level, we needed 235 patients per group with a trial of two 
parallel, individually randomised groups (nQuery Advisor [2005] v6.0, Los Angeles, CA). 
We applied an inflation factor, taking into account that the trial was clustered and it was a 
cross-over trial [25-26]. We considered a high value for the intraclass correlation coefficient 
(ICC) because the primary outcome was a process and because of the expected incidence of 




correlation for the intra-cluster inter-period correlation, that is, half the intra-cluster intra-
period correlation. We initially expected to involve 42 units, for a required number of 10.2 
patients in each unit for each period. Because we aimed to perform a statistical analysis on the 
completer population, we planned to recruit 14 patients in each unit in each period, for a total 
of 1,176 patients. 
Statistical analysis 
Data are reported as median (interquartile range [IQR]), number (%) and odds ratios (ORs) or 
relative risk (RR), with 95% confidence intervals (CIs). Data analysis was based on an 
“intention-to-treat” strategy. Missing data were handled considering a best-case scenario (i.e., 
a missing outcome, meaning no problem). The number of problems was analysed by using a 
mixed logistic model with both the group and the period considered as fixed effects and the 
cluster and the interaction terms cluster*period as random effects. ICCs were estimated per 
group by using the Zou et al. approach [27]. We performed a sensitivity analysis excluding 
patients with missing data and also pre-specified subgroup analyses (medical vs surgical 
units; patients < 75 vs ≥ 75 years old; patients with < 5 vs ≥ 5 drugs prescribed at discharge). 
Secondary outcomes were analysed by using the same approach as for the primary outcome 
except for the number of problems per patients for which a mixed Poisson model was fitted. 
Analyses involved use of SAS v9.2 and R v3.1.2. 
RESULTS 
Participants 
From January 2014 to March 2015, we enrolled 1,092 patients in 48 units from 22 hospitals: 
538 in the intervention group and 554 in the control group (Figure 4). Twelve hospitals were 
university hospitals, nine were general hospitals and one was a military teaching hospital. 
Twenty-nine units were medical units and 19 were surgical ones. Three patients (two in the 
intervention group and one in the control group) refused their data to be used and were thus 
excluded from any analyses. The median number of patients per period per cluster in the 
intervention and control groups was 11.5 (IQR 7.0 to 15.0) and 11.5 (7.5 to 15.0) respectively. 
Patient characteristics are reported in Table 1. The median number of drugs at discharge in the 





The number of patients with at least one drug-related problem in the intervention and control 
groups was 236 (44.0%) and 280 (50.6%) respectively (OR 0.77, 95% CI 0.61 to 0.98). The 
intervention reduced the frequency of prescription and/or dispensing errors, patient errors and 
treatment gaps (OR 0.52, 95% CI 0.29 to 0.93; 0.84, 0.66 to 1.07; and 0.65, 0.43 to 0.99, 
respectively; Table 2). Within-period and between-period intra-cluster correlation coefficients 
are reported in Table3. Sensitivity analyses excluded 39 patients (18 and 21 in the 
intervention and control groups) and led to consistent results. Subgroup analyses are reported 
in Figure 5. We found no significant interaction. The number of patient errors was 







Potential iatrogenic exposure 
Considering severe iatrogenic drug-related problems (score 2 or 3 on the NCC MERP 
classification), 28 (5.2%) and 48 (8.7%) patients in the intervention and control groups had at 
least one severe iatrogenic problem (OR 0.57, 95% CI 0.35 to 0.93) (Table5 and Table6). 
Secondary outcomes 
Unplanned hospitalisations at day 35 
At day 35, 31 (5.8%) versus 25 (4.5%) patients in the intervention and control groups had an 
unplanned hospitalisation (OR 1.46, 95% CI 0.91 to 2.35). For 9 patients, we could not 
conclude on a planned or unplanned hospitalisation. 
Proportion of drug prescriptions modified by the hospital pharmacist at discharge 
In the intervention group, hospital pharmacists modified the drug prescription at discharge for 
99 patients (18.5%, 95% CI 12.8 to 25.1). 
Time spent by hospital pharmacist 
The median time dedicated by the hospital pharmacist for medication reconciliation at 
discharge and communication to the community pharmacist was 20 min (IQR 15 to 30). The 
estimated ICC was 0.493 (95% CI 0.419 to 0.577), which means that 49.3% of the variability 
in time spent was due to hospital pharmacists and the remaining 50.7% to heterogeneity in 
patient characteristics. 
Satisfaction 
Overall, 465/494 intervention patients who responded (94.1%, 95% CI 91.7 to 96.0) versus 
494/524 control patients (94.3%, 95% CI 91.5 to 96.4) were very satisfied or satisfied with 
their medication management. Also, 439/447 intervention patients (98.2%, 95% CI 96.1 to 
99.4) were very satisfied or satisfied that their prescriptions had been transmitted to their 
community pharmacist, and 391/397 (98.5%, 95% CI 96.0 to 99.8) were very satisfied or 
satisfied with the explanations given by the hospital pharmacist before their discharge. 
Among community pharmacists for the intervention group who responded, 390/409 (95.4%, 








In this cluster randomised superiority trial, association of medication reconciliation at 
discharge and communication from the hospital to the community pharmacist decreased drug-
related problems and severe iatrogenic problems.  
In terms of our composite outcome, we observed a significant effect of the intervention on 
prescribing/dispensing errors and treatment gap but not on patient errors. Although the 
proportion of patients with at least one home medication error did not significantly decrease, 
the overall number of errors significantly decreased by 22% (RR 0.78, 95% CI 0.67 to 0.96). 
When implementing a liaison from the hospital to community pharmacist associated with 
systematic medication reconciliation, Van Hollebeke et al. observed a large decrease in 
proportion of patients with at least one medication shortage during the 7 days after discharge 
(from 22% to 2%) [28]. However, this study was a single-centre trial, which limits its external 
validity. Duggan et al., conducted a similar study except that it was single-center and only for 
medical patients [29]. They demonstrated a decrease in discrepancies at discharge (32.2% vs 
52.7% for prescribed drugs) when the patients received a copy of a letter listing their drugs 
prescribed at discharge and handed it to their regular community pharmacist. Walker et al. 
assessed an intervention including therapy assessment, medication reconciliation, counselling 
and education and finally post-discharge follow-up in patients with more than three prescribed 
drugs [24]. The authors observed a decrease from 59.6% to 33.5% in the proportion of 
patients with at least one discrepancy. Nevertheless, this study took place in the United States, 
whose health system differs from that in France where drugs are free of charge. 
We observed a greater effect among surgical than medical hospital units (OR 0.64 vs 0.86), 
although the difference was not significant, probably because of lack of power. Sebaaly et al. 
identified more medication errors at discharge in surgical than medical units, although the 
difference was also not significant [30]. We also observed a smaller effect for patients ≥ 75 
versus < 75 years old, although once again, the difference was not significant. Finally, the 
effect did not appear to be related to the number of drugs, with similar ORs for ≥ 5 and < 5 
drug subgroups. These latter results do not fully agree with the Hias et al. study, that showed 
that the number of drugs at admission and patient age were associated with drug-related 
problems at admission [31]. 
Our trial shows a reduction in potential severe iatrogenic problems with the intervention. A 
similar result was observed in the Phatak et al. randomised trial assessing a complex 






events reduced from 12.8% to 8% [14]. Sebaaly et al. classified 6% of medication errors as 
serious or lethal in their study [32]. These results confirm the relevance of our intervention to 
decrease patient exposure to serious drug-related problems. 
Concerning the time spent by the hospital pharmacist on the intervention, Zemaitis et al. 
found a mean of 10.1 min dedicated to medication reconciliation at discharge and 6.6 min to 
medication reconciliation at admission [4]. In our study, the median time spent by the hospital 
pharmacist was 20 min for the whole process, including communication with the community 
pharmacist. However, such a global median masks very different situations with high inter-
hospital variability in time spent. 
As in other studies [32; 35], we did not demonstrate a reduction in unplanned hospitalisations 
at day 35 after discharge. Overall, we observed a global rate of unplanned hospitalisations of 
5.1% as compared with previously reported  rates of 2.7% and 2.8% at 7 and 30 days, 
respectively, for all causes of hospitalisations (except recovery and psychiatric stays) in 
France [33-34]. The difference may be due to the way we assessed this outcome, directly from 
the patient. In their review, Christensen and Lundh explained the lack of evidence on 
unplanned hospitalisations as being due to low-quality trials and too-short follow-up: 1 year 
would be a better follow-up [36]. Arnold et al. observed a decrease from 19.5% to 9.2% in 
readmission rate at day 30 after discharge, but data were collected from physicians or 
pharmacists involved in clinical pharmacy, rather than from patients themselves [37].  
Unlike other trials we didn’t find a relationship between the number of drugs prescribed at 
discharge and the occurrence of DRPs, nor did we observe a relationship with age [38-39]. 
However, we observed a greater effect in surgical units as compared to medical ones, 
knowing that patients discharged from surgical wards are generally younger than those 
discharged from medical ones, and have fewer drugs. Therefore the type of unit 
(surgical/medical) may acts as a confounding factor when studying the relationship between 
the number of drugs or age and the number of DRPs. 
Generalisability 
Our study involved hospital pharmacists from 22 university and general hospitals. Units were 
representative of existing medical or surgical specialities, and eligibility criteria for patients 
were sufficiently extensive for intervention generalization in French hospitals. Community 






patients they typically provide drugs to were recruited in the study. These elements offer good 
external validity to our trial. Moreover each cluster was its own comparator because of the 
cross-over design, which helped achieve good baseline balance in this non-blinded study, thus 
limited bias.  
Limitations 
Medication reconciliation at admission is considered good practice [40]; therefore, we did not 
exclude units in which it was usual care. Hence, we included one unit with medication 
reconciliation at admission. Nevertheless, because the study was cross-over, there is no reason 
to believe that this was source of bias.  
We did not communicate the medication reconciliation synthesis to the patient’s general 
practitioner, who was not involved in the present study. General practitioners receive a 
hospitalisation report with information about their patient’s hospital stay, but generally at 1 to 
4 weeks after hospital discharge. Our aim was to focus on the patient community pharmacist, 
who generally is the first healthcare person the patient meets after hospital discharge. 
For logistical convenience, units were sequentially activated. Hence, when the last unit was 
activated, patient recruitment in the first unit had ended for more than 12 months. Such a 
situation may have induced between-unit contamination but this remains highly theoretical 
since units activated at different times were from different hospitals, with different hospital 
pharmacists. This sequential activation may have also affected how the intervention was 
applied, since hospital pharmacists were all informed together about the intervention, at the 
beginning of the study. To limit this problem, before activation of each unit, a phone meeting 
was organized to remind how the study had to be conducted and what were the intervention 
components. 
Future research 
Although we demonstrated the efficiency of our intervention for drug-related problems, we 
failed to observe a benefit for unplanned hospitalisation. As explained, this outcome was 
assessed in a non-optimal way (asking patients or their caregiver) and after a too-short follow-
up. More work is undoubtedly needed on this outcome, relating it to severe iatrogenic 







Systematic medication reconciliation at discharge along with community-pharmacist contact 
is beneficial for patients. Since the end of this trial and the first results communicated in 
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Table 1: Characteristics of patients in intervention and control groups 
Characteristics 
Control/intervention sequence   Intervention/control sequence 
Period 1: Control Period 2: Intervention  Period 1: Intervention Period 2: Control 
24 units, n=307 24 units, n=258   24 units, n=278 24 units, n=246 
No. of patients per cluster - median [Q1-Q3] 13.0 [9.0-15.0] 10.5 [7.0-14.5]  11.0 [2.0-14.0] 13.0 [7.5-15.5] 
Men - n (%) 157 (51.1) 138 (53.5)  158 (56.8) 145 (58.9) 
Age - mean (SD) 61.5 (17.0) 61.7 (16.1)  64.7 (17.0) 62.7 (16.4) 
Autonomous patient - n(%) 278 (90.6) 239 (92.6)  250 (89.9) 237 (96.4) 
No. of drugs at admission - median [Q1-Q3] 5.0 [3.0-8.0] 5.0 [2.0-8.0]  5.0 [3.0-9.0] 5.0 [2.0-8.0] 
No. of drugs at discharge - median [Q1-Q3] 5.0 [2.0-8.0] 5.0 [3.0-8.0]†  5.0 [3.0-9.0] 4.0 [3.0-7.0] 
Discharge before 1 pm - n (%) 85 (27.8)* 65 (25.2)   64 (23.0) 61 (24.8) 








Table 2: Drug-related problems observed during the 7 days after hospital discharge 
Outcome 
Control/Intervention sequence   Intervention/Control sequence 












24 units, n=307 24 units, n=258   24 units, n=278 24 units, n=246 
At least one drug-related 
problem (ITT) 160 (52.1) 115 (44.6)  121 (43.5) 120 (48.8) -6.55 (-12.49;-0.60) 0.77 (0.61;0.98) 
At least one 
prescription/dispensation 
problem 18 (5.9) 5 (1.9)  13 (4.7) 17 (6.9) -3.19 (-5.71;-0.67) 0.52 (0.29;0.93) 
At least one patient error 142 (46.3) 104 (40.3)  107 (38.5) 100 (40.7) -4.27 (-10.1;1.59) 0.84 (0.66;1.07) 
At least one treatment 
missing 36 (11.7) 25 (9.7)  16 (5.8) 27 (11.0) -3.48 (-6.95;-0.01) 0.65 (0.43;0.99) 
        
 24 units, n=263 24 units, n=233  24 units, n=242 24 units, n=233   
At least one drug-related 







Table 3: Within-period and between-period intra-cluster correlation coefficients 
Outcome Within-period correlation Between-period correlation 
At least one drug-related problem (ITT) n=1089 0.022 [0.000;0.051] 0.003 [0.000;0.012] 
At least one prescription/dispensation problem 0.000 [0.000;0.019] 0.000 [0.000;0.014] 
At least one patient error 0.019 [0.000;0.053] 0.002 [0.000;0.013] 
At least one treatment missing 0.029 [0.000;0.070] 0.015 [0.000;0.037] 
At least one drug-related problem (completers) n=971 0.030 [0.000;0.065] 0.004 [0.000;0.015] 
ITT, intention to treat 






Table 4: Number of patient errors in the intervention and control groups. 
  
Control/intervention sequence   Intervention/control sequence 
Period 1: Control Period 2: Intervention  Period 1: Intervention Period 2: Control 
24 units, n=307 24 units, n=258   24 units, n=278 24 units, n=246 
No. of patients with at least one 
medication error after discharge 
142 (46.3) 104 (40.3)  107 (38.5) 100 (40.7) 
No. of errors per patient      
1 68 (47.9) 62 (59.6)  66 (61.7) 49 (49.0) 
2 46 (32.4) 24 (23.1)  25 (23.4) 27 (27.0) 
3 20 (14.1) 14 (13.5)  15 (14.0) 16 (16.0) 
4 4 (2.8) 2 (1.9)  1 (0.9) 5 (5.0) 
5 1 (0.7) 1 (1.0)  0 (0.0) 1 (1.0) 
6 3 (2.1) 0 (0.0)  0 (0.0) 2 (2.0) 
7 0 (0.0) 1 (1.0)  0 (0.0) 0 (0.0) 








Table 5: Potential exposure to iatrogenic events by National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) classification 
[20] in the intervention and control groups. 
NCC MERP score Interventio
n 
Control 
0, exposure to at least one drug-related problem with no potential 
harm 
66 (12.3)  65 (11.8)) 
1, exposure to at least one drug-related problem with low 
potentiality of harm 
142 (26.5) 167 (30.2) 
2, exposure to at least one drug-related problem with significant 
potentiality of harm 
28 (5.2) 45 (8.1) 
3, exposure to at least one drug-related problem with global 
impact potentially life-threatening 
0 (0) 3 (0.5) 
Patients not exposed to a drug-related problem 300 (56.0) 273 (49.4) 








Table 6: Potential exposure to iatrogenic events by NCC MERP classification scale scores [20] in the intervention and control groups. 
  









24 units, n=307 24 units, n=258   24 units, n=278 24 units, n=246 
0, exposure to at least one drug-related 
problem with no potential harm 37 (23.1) 27 (23.5)  39 (32.2) 28 (23.3) 
1, exposure to at least one drug-related 
problem with low potentiality of harm 96 (60.0) 71 (61.7)  71 (58.7) 71 (59.2) 
2, exposure to at least one drug-related 
problem with significant potentiality of 
harm 
26 (16.3) 17 (14.8)  11 (9.1) 19 (15.8) 
3, exposure to at least one drug-related 
problem with global impact potentially life-
threatening 
1 (0.6) 0 (0.0)   0 (0.0) 2 (1.7) 
Patients not exposed to a drug-related 
problem 













Figure 1: Timeline cluster diagram 
Figure 2: Flow chart of the intervention 
Figure 3: the pharmacist intervention (French Society of Clinical Pharmacy) 
Figure 4: Flow-chart of the study. 








Ethical approval: The protocol was approved by the local ethics committee (CPP TOURS -
Region Centre - Ouest 1) for all centers. 
This article respects the CONSORT checklist of information to include when reporting a 
cluster randomised trial; Bruno Giraudeau is garant of it.  
  
Protocol 
The initial protocol was in French, and is available from Xavier Pourrat on request. It was 








































Figure 5: sub-groups analyses 
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